ProKidney Corp. - Class A Ordinary Shares PROK 深 滬
等待開盤 09-05 09:30:00 美东时间
2.285
-0.075
-3.18%
華盛通- 最 高2.38
- 今 開2.38
- 成交量 64.00万股
- 最 低 2.25
- 昨 收 2.36
- 總市值 3.04亿
- 52周最高 7.13
- 市盈率 靜 --
- 換手率 0.48%
- 52周最低 0.4603
- 委 比 15.01%
- 總股本 1.33亿
- 歷史最高 14.19
- 量 比 1.02
- 振 幅 5.51%
- 歷史最低 0.4603
- 每 手 1
- 風險率 0.80%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference
ProKidney Corp., a leader in cellular therapeutics for chronic kidney disease, announced that senior management will participate in two upcoming healthcare conferences: the Citi Biopharma Back to School Conference in Boston on September 3, 2025, and the Morgan Stanley Global Healthcare Conference in New York on September 8, 2025. Both events will feature fireside chat sessions available via live webcast. Additional details, including webcast link...
08-27 11:30
Chamath Palihapitiya Returns To SPACs: Past 18 Deals, Investments Average Loss Of 14%
Chamath Palihapitiya is back with a new SPAC. Many investors will remember past SPACs the investor was involved with and the poor performance track record.
08-19 23:53
Watching ProKidney Corp; Zacks Upgrades Stock To Strong Buy
https://www.zacks.com/stock/news/2589077/prokidney-cp-prok-upgraded-to-strong-buy-what-does-it-mean-for-the-stock
07-17 23:52
UBS Maintains Buy on ProKidney, Raises Price Target to $8
UBS analyst Eliana Merle maintains ProKidney (NASDAQ:PROK) with a Buy and raises the price target from $4 to $8.
07-15 22:23
Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining ar...
07-15 20:40
ProKidney Confirms Alignment With FDA On Accelerated Approval Pathway For Rilparencel
FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD and type 2 diabetesFDA also confirmed that the ongoing Phase 3 PROACT 1 study can be used for
07-15 19:31
ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel
ProKidney Corp. announced alignment with the FDA on the accelerated approval pathway for rilparencel, an autologous cellular therapy for chronic kidney disease (CKD) with type 2 diabetes. The FDA confirmed that the slope of estimated glomerular filtration rate (eGFR) from the Phase 3 PROACT 1 study can serve as a surrogate endpoint for accelerated approval, with nearly half of required patients enrolled. Topline data for the accelerated approval ...
07-15 11:30
ProKidney Enters New $200M Sale Agreement with Jefferies
ProKidney ( ($PROK) ) has issued an update. On July 14, 2025, ProKidney Corp. e...
07-15 05:27
美股大行评级 | 潜在涨幅107.37%！花旗上调ProKidney目标价至9美元，维持"买入"评级
今日重点评级关注：花旗：维持ProKidney Corp. - Class A Ordinary Shares"买入"评级，目标价从6美元升至9美元；Canaccord Genuity：维持e.l.f. Beauty"买入"评级，目标价从114美元升至150美元
07-10 09:55
盘前：股指期货变动不大 交易员仍在努力摆脱关税动荡影响
周四，股指期货变动不大，交易员仍在努力摆脱关税动荡的影响。此前一天，在英伟达的带动下，纳斯达克综合指数创下新高。 截至发稿，道指期货跌0.04%，标普...
07-10 20:08
